Clinical Trial Update: Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating dacomitinib for metastatic non-small cell lung cancer with EGFR activating mutations in India has completed with posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non Small Cell Lung Cancer

Drugs mentioned

• Dacomitinib (dacomitinib)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Non Small Cell Lung Cancer | Phase 4 | Status: COMPLETED | Results posted: 2024-04-05